scholarly journals Thyroid transcription factor 1 and p63 expression is associated with survival outcome in patients with non‑small cell lung cancer treated with erlotinib

2020 ◽  
Vol 20 (2) ◽  
pp. 1376-1382
Author(s):  
Martin Svaton ◽  
Ondrej Fiala ◽  
Gabriela Krakorova ◽  
Jiri Blazek ◽  
Karolina Hurdalkova ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Transcription Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Survival Outcome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1

scholarly journals Thyroid Transcription Factor-1 Expression in Advanced Non-Small Cell Lung Cancer: Impact on Survival Outcome

2015 ◽  
Vol 16 (7) ◽  
pp. 2987-2991 ◽  
Author(s):  
Shereef Ahmed Elsamany ◽  
Turki M Al-Fayea ◽  
Abdullah Said Alzahrani ◽  
Waleed Nabeel Abozeed ◽  
Waseem Darwish ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Transcription Factor ◽  
Small Cell Lung Cancer ◽  
Survival Outcome ◽  
Small Cell ◽  
Small Cell Lung ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Impact On Survival ◽  
Transcription Factor 1

scholarly journals Thyroid transcription factor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy

Tumor Biology ◽  
2017 ◽  
Vol 39 (2) ◽  
pp. 101042831769118 ◽  
Author(s):  
Ondrej Fiala ◽  
Milos Pesek ◽  
Jana Skrickova ◽  
Vitezslav Kolek ◽  
Frantisek Salajka ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Transcription Factor ◽  
Small Cell Lung Cancer ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Small Cell ◽  
Small Cell Lung ◽  
Thyroid Transcription Factor 1 ◽  
Thyroid Transcription Factor ◽  
Transcription Factor 1

Pemetrexed is an antifolate cytostatic agent targeting several folate-dependent enzymatic pathways, widely used in the treatment of locally advanced or metastatic stage non-small cell lung cancer. Aside from the non-squamous histology, there is still no available molecular biomarker predicting treatment efficacy of pemetrexed-based chemotherapy. The aim of our retrospective study was to evaluate the association of thyroid transcription factor 1 expression with outcome of a large cohort of patients with non-squamous non-small cell lung cancer treated with pemetrexed. We retrospectively analysed clinical data of 463 patients with advanced-stage non-small cell lung cancer (IIIB or IV) treated with pemetrexed-based chemotherapy. Thyroid transcription factor 1 expression was assessed using indirect immunohistochemical detection in formalin-fixed paraffin-embedded tumour tissue at the time of diagnosis. Thyroid transcription factor 1 expression was detected in the tumour tissue from 76.0% of patients, and tumours from 24.0% of patients were thyroid transcription factor 1 negative. The median progression-free survival and overall survival for patients with thyroid transcription factor 1 positive tumours were 4.8 and 11.8 months compared to 2.8 and 8.3 months for those with thyroid transcription factor 1 negative tumours (p = 0.001 and p < 0.001). The multivariable Cox proportional hazards model revealed that thyroid transcription factor 1 expression was significantly associated with progression-free survival (hazard ratio = 1.57, p < 0.001) and also with overall survival (hazard ratio = 1.73, p < 0.001). In conclusion, the results of the conducted retrospective study suggest that the thyroid transcription factor 1 expression was independently associated with progression-free survival and overall survival in patients with advanced-stage non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy.

Sign in / Sign up

Export Citation Format

Share Document